Tackling Drug Resistance in Cancer Treatment – Stefanie Flückiger

Stefanie Flückiger, co-founder and CEO of Tolremo Therapeutics, is transforming cancer treatment with her innovative biotech company. Discover how Tolremo, an ETH spinoff, is tackling non-genetic drug resistance with cutting-edge technology. Hear about Stefanie's unique journey from academia to entrepreneurship, the impact of diversity in driving innovation, and the intriguing science behind cancer cells' resistance to drugs.This is her story.Chapters:(01:06) The Role of Awards and Female Leadership(03:52) Diversity in Leadership and Innovation(06:21) The Catalyst for Starting Tolremo(10:30) Understanding Cancer Cell Resistance(15:30) From Academia to Biotech: The Journey of Tolremo(19:47) Stephanie's Academic Background and ETH Experience(22:34) Closing Thoughts and Personal InsightsBooks mentioned:Why We Sleep by Matthew WalkerPodcast mentioned:Huberman Lab Podcast

Episode metadata supplied by the publisher feed · Published Oct 3, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Tackling Drug Resistance in Cancer Treatment – Stefanie Flückiger

0:00 26:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of We Are ETH?

This episode is 26 minutes long.

When was this We Are ETH episode published?

This episode was published on October 3, 2024.

Can I download this We Are ETH episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!